Acriflavine, a clinically aproved drug, inhibits SARS-CoV-2 coronavirus and other betacoronaviruses March 22, 2021August 8, 2022 Coronaheadsup.com Coronavirus, Health, Treatment We show that acriflavine inhibits viral replication at nanomolar concentration in cellular models, in vivo in mice and ex vivo in human airway epithelia, with broad range activity against SARS-CoV-2 and other betacoronaviruses. Full biorxiv.org preprint ** This post was originally published on March 22, 2021 **Share this:Post Related Posts: Research: Remdesivir-induced emergence of SARS-CoV2 variants in patients with prolonged infectionUSA: 14-year-old tiger dies of Covid-19 in Ohio zooPaxlovid: Covid-19 infections rebounding a few days after treatment *4 UPDATES*Vietnam: Severe liver and brain damage in child after Covid-19 infectionAustralia: 58% seek advice for ongoing Covid symptomsPaxlovid: Virologic characterization of nirmatrelvir-ritonavir rebound
